There is also an excessive level of NDMA in metformin! FDA requires 5 companies to recall

The FDA announced that testing of the slow-release metformin drug found that some metformin products contained higher levels of NDMA than the body's acceptable daily intake as prescribed by regulatorsThe NDMA is also the root cause of the previous U.Srecall of high blood pressure and heartburn drugsU.Sregulators said they were in contact with the company that makes the drug to start a drug recallMetformin is a common drug used to control blood sugar in people with type 2 diabetes and is produced by several companiesLast year, about 21 million prescription drugs were used for a slow release version of the drug, about a quarter of all prescriptions for metformin in the United States, Bloomberg reportedA recall of metformin is expected to begin this week, Bloomberg saidFDA spokeswoman Sarah Peddicord said the rapid release of metformin was tested and no carcinogen levels were found to be higher than normalOn Thursday (May 28), the FDA announced that it has recommended that five pharmaceutical companies voluntarily recall the diabetes drug metforminThe FDA said it would post a specific recall notice on its website and revealed that one of them was a metformin tablet from Canadian company Apotex Corp, which the other four companies have not disclosedBut the FDA also cautions consumers that even in the event of a recall, patients should continue to take metformin tablets until medical professionals help find alternativesIn February, the FDA said it had found no problems with the carcinogen in its investigation of metformin samplesHowever, an independent survey conducted in March by Valisure, an online pharmacy, showed high levels of NDMA in metformin produced by 11 companies, including Amneal Pharmaceuticals Inc and Aurobindo Pharma LtdIf the recall occurs, metformin will be the third widely used drug affected by NDMA-related contamination in the past two years.